Real-life data on efficacy and safety of original Adalimumab and biosimilar Adalimumab (ABP 501) in pediatric rheumatic diseases.

Ulu, Kadir; Çakan, Mustafa; Çaglayan, Sengül; Yigit, Ramazan Emre; Demir, Ferhat; Coskuner, Taner; Kardes, Esra; Sözeri, Betül

Ulu, Kadir; Çakan, Mustafa; Çaglayan, Sengül; Yigit, Ramazan Emre; Demir, Ferhat; Coskuner, Taner; Kardes, Esra; Sözeri, Betül.

Afiliação

Ulu K; Department of Pediatric Rheumatology, University of Health Sciences, Ümraniye Training and Research Hospital, Istanbul, Turkey.
Çakan M; Department of Pediatric Rheumatology, University of Health Sciences, Ümraniye Training and Research Hospital, Istanbul, Turkey.
Çaglayan S; Department of Pediatric Rheumatology, University of Health Sciences, Ümraniye Training and Research Hospital, Istanbul, Turkey.
Yigit RE; Department of Pediatric Rheumatology, University of Health Sciences, Ümraniye Training and Research Hospital, Istanbul, Turkey.
Demir F; Department of Pediatric Rheumatology, University of Health Sciences, Ümraniye Training and Research Hospital, Istanbul, Turkey.
Coskuner T; Department of Pediatric Rheumatology, University of Health Sciences, Ümraniye Training and Research Hospital, Istanbul, Turkey.
Kardes E; Department of Ophthalmology, University of Health Sciences, Ümraniye Training and Research Hospital, Istanbul, Turkey.
Sözeri B; Department of Pediatric Rheumatology, University of Health Sciences, Ümraniye Training and Research Hospital, Istanbul, Turkey.

Expert Opin Biol Ther ; 23(8): 833-839, 2023.

Article em En | MEDLINE | ID: mdl-36101926

Palavras-chave

ABP 501; adalimumab; biosimilar; juvenile idiopathic arthritis; uveitis

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Expert Opin Biol Ther Assunto da revista: BIOLOGIA / TERAPEUTICA Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Turquia

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google